News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Oxford BioMedica PLC Clarifies Trovax® Strategy
October 28, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Oxford BioMedica (LSE: OXB), the leading gene therapy company, provides clarification of its strategy for its lead cancer immunotherapy, TroVax.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Cancer
RevMed’s Rasonque gets a subtype data asterisk, but analysts remain bullish
October 12, 2026
·
2 min read
·
Michael Gibney
Radiopharma
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
October 12, 2026
·
2 min read
·
Gabrielle Masson
IN PARTNERSHIP WITH ROSE BIOSOLUTIONS
Successful CDMO partnerships hinge on honest—and sometimes critical—support
October 12, 2026
·
5 min read
·
Jennifer C. Smith-Parker
IPO
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
October 9, 2026
·
3 min read
·
Gabrielle Masson
